Cargando…

A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides

Intrathecal administration is an important mode for delivering biological agents targeting central nervous system (CNS) diseases. However, current clinical practices lack a sound theorical basis for a quantitative understanding of the variables and conditions that govern the delivery efficiency and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Linninger, Andreas A., Barua, Dipak, Hang, Yaming, Iadevaia, Sergio, Vakilynejad, Majid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272745/ https://www.ncbi.nlm.nih.gov/pubmed/37334053 http://dx.doi.org/10.3389/fphys.2023.1130925

Ejemplares similares

Determination of spinal tracer dispersion after intrathecal injection in a deformable CNS model
por: Ayansiji, Ayankola O., et al.
Publicado: (2023)

Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease
por: Stoker, Thomas B., et al.
Publicado: (2020)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
por: Biliouris, Konstantinos, et al.
Publicado: (2018)

Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease
por: Keating, Michael F., et al.
Publicado: (2022)

Pharmacokinetic Studies of Antisense Oligonucleotides Using MALDI-TOF Mass Spectrometry
por: Herkt, Markus, et al.
Publicado: (2020)

Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system
por: Sullivan, Jenna M., et al.
Publicado: (2020)

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
por: Yu, Rosie Z., et al.
Publicado: (2020)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
por: Scaglioni, Dominic, et al.
Publicado: (2021)

A mechanistic study on the cellular uptake, intracellular trafficking, and antisense gene regulation of bottlebrush polymer-conjugated oligonucleotides
por: Zhang, Lei, et al.
Publicado: (2022)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson’s disease
por: Pavia-Collado, Rubén, et al.
Publicado: (2022)

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients
por: Saleem, Azeem, et al.
Publicado: (2011)

Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides
por: Uemura, Yasunori, et al.
Publicado: (2019)

A computational model of cerebrospinal fluid production and reabsorption driven by Starling forces
por: Buishas, Joel, et al.
Publicado: (2014)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
por: Pauli, Andrea, et al.
Publicado: (2015)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017)

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012)

Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement
por: Batista-Duharte, Alexander, et al.
Publicado: (2020)

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
por: Gagliardi, Maria, et al.
Publicado: (2021)

Inactivating Gene Expression with Antisense Modified Oligonucleotides
por: Altman, Sidney, et al.
Publicado: (2021)

Antisense Oligonucleotide-Based Therapy of Viral Infections
por: Tarn, Woan-Yuh, et al.
Publicado: (2021)

Nonviral delivery systems for antisense oligonucleotide therapeutics
por: Huang, Si, et al.
Publicado: (2022)

Antisense oligonucleotide therapy for KCNT1 encephalopathy
por: Burbano, Lisseth Estefania, et al.
Publicado: (2022)

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
por: Goyenvalle, Aurélie, et al.
Publicado: (2023)

Pharmacokinetics and Disposition of Heparin-Binding Growth Factor Midkine Antisense Oligonucleotide Nanoliposomes in Experimental Animal Species and Prediction of Human Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model
por: Bai, Haihong, et al.
Publicado: (2021)

A Mechanistic Model of Early FcεRI Signaling: Lipid Rafts and the Question of Protection from Dephosphorylation
por: Barua, Dipak, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nng0sgq62rk8pqb5d10etcecjs